Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Dana Pe'er

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9259-8817; OpenAlex author ID A5074451448; NIH RePORTER profile ID 8951734. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 1)
Trials
0
Grants
2
Labs led
1
Collaborators
55
Papers, trials and grants by year

2022: 1 paper, 1 grant · 2023: none · 2024: none · 2025: 1 paper · 2026: 5 papers, 1 grant

Papers 7

  1. Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial. Co-author DOI 10.1038/s41591-026-04299-5↗
  2. Transcriptomic Plasticity Is a Hallmark of Metastatic Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-25-1117↗
  3. POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer Co-author DOI 10.64898/2026.03.15.711961↗
  4. Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer Co-author DOI 10.64898/2026.08.06.26359422↗
  5. Neoantigen-reactive CD8 + T cell engagement marks exceptional survivors of pancreatic cancer Co-author DOI 10.64898/2026.09.17.752426↗
  6. SMAD4 induces opposite effects on metastatic growth from pancreatic tumors depending on the organ of residence. Co-author DOI 10.1038/s43018-025-01047-5↗
  7. Systematic Comparison of Pancreatic Ductal Adenocarcinoma Models Identifies a Conserved Highly Plastic Basal Cell State. Co-author DOI 10.1158/0008-5472.can-22-1742↗

Grants 2

  1. Mechanisms of p53 Engagement and Action at the Benign-to-Malignant Transition in Sporadic Tumorigenesis R01CA283378↗
  2. Data Processing, Analysis and Modeling Unit U2CCA233284↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Christine A. Iacobuzio–Donahue · 5 shared papers, 1 shared grant, 2022–2026 · strength 1.57
  2. Scott W. Lowe · 1 shared paper, 1 shared grant, 2025–2026 · strength 1.45
  3. Wungki Park · 3 shared papers, 2026 · strength 0.60
  4. Eileen Mary O'Reilly · 3 shared papers, 2026 · strength 0.60
  5. Akimasa Hayashi · 2 shared papers, 2026 · strength 0.42
  6. Arnav Mehta · 2 shared papers, 2026 · strength 0.41
  7. Benjamin D. Greenbaum · 2 shared papers, 2026 · strength 0.37
  8. Olca Baştürk · 2 shared papers, 2026 · strength 0.37
  9. Marinela Capanu · 2 shared papers, 2026 · strength 0.37
  10. Vinod P. Balachandran · 2 shared papers, 2026 · strength 0.37
  11. Kevin C. Soares · 2 shared papers, 2026 · strength 0.37
  12. Benoı̂t Rousseau · 2 shared papers, 2026 · strength 0.37
  13. Marc Hilmi · 2 shared papers, 2026 · strength 0.37
  14. Nuray Tezcan · 2 shared papers, 2026 · strength 0.37
  15. Fiyinfolu O. Balogun · 2 shared papers, 2026 · strength 0.37
  16. Kenneth H. Yu · 2 shared papers, 2026 · strength 0.37
  17. Alejandro Jiménez-Sánchez · 1 shared paper, 2026 · strength 0.23
  18. Jungeui Hong · 1 shared paper, 2026 · strength 0.23
  19. Anna M. Varghese · 1 shared paper, 2026 · strength 0.19
  20. Fergus Keane · 1 shared paper, 2026 · strength 0.19
  21. Caitlin A. McIntyre · 1 shared paper, 2026 · strength 0.19
  22. Haochen Zhang · 1 shared paper, 2026 · strength 0.19
  23. Danny N. Khalil · 1 shared paper, 2026 · strength 0.19
  24. Michael Jon Pishvaian · 1 shared paper, 2026 · strength 0.19
  25. Vaia Florou · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.